about
Edible Ginger-derived Nano-lipids Loaded with Doxorubicin as a Novel Drug-delivery Approach for Colon Cancer TherapyInhibition of MDR1 gene expression and enhancing cellular uptake for effective colon cancer treatment using dual-surface-functionalized nanoparticles.Intestinal epithelial CD98 synthesis specifically modulates expression of colonic microRNAs during colitis.Hyaluronic acid-functionalized polymeric nanoparticles for colon cancer-targeted combination chemotherapy.Co-delivery of camptothecin and curcumin by cationic polymeric nanoparticles for synergistic colon cancer combination chemotherapy.Intestinal epithelial CD98 directly modulates the innate host response to enteric bacterial pathogens.Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model.Mannosylated bioreducible nanoparticle-mediated macrophage-specific TNF-α RNA interference for IBD therapyCombination Therapy for Ulcerative Colitis: Orally Targeted Nanoparticles Prevent Mucosal Damage and Relieve Inflammation.Targeting intestinal inflammation with CD98 siRNA/PEI-loaded nanoparticles.Glycoprotein CD98 as a receptor for colitis-targeted delivery of nanoparticle.Oral colon-specific therapeutic approaches toward treatment of inflammatory bowel disease.Nanoparticles with surface antibody against CD98 and carrying CD98 small interfering RNA reduce colitis in mice.Nanoparticle-mediated co-delivery of chemotherapeutic agent and siRNA for combination cancer therapy.Fab'-bearing siRNA TNFα-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis.Oral delivery of curcumin via porous polymeric nanoparticles for effective ulcerative colitis therapy.Acid-Activatable Theranostic Unimolecular Micelles Composed of Amphiphilic Star-like Polymeric Prodrug with High Drug Loading for Enhanced Cancer Therapy.iRGD-functionalized PEGylated nanoparticles for enhanced colon tumor accumulation and targeted drug delivery.Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis.Effects of tripolyphosphate on cellular uptake and RNA interference efficiency of chitosan-based nanoparticles in Raw 264.7 macrophages.A Hyaluronidase-Responsive Nanoparticle-Based Drug Delivery System for Targeting Colon Cancer Cells.TNFα gene silencing mediated by orally targeted nanoparticles combined with interleukin-22 for synergistic combination therapy of ulcerative colitisSilencing of Intestinal Glycoprotein CD98 by Orally Targeted Nanoparticles Enhances Chemosensitization of Colon CancerIrinotecan delivery by unimolecular micelles composed of reduction-responsive star-like polymeric prodrug with high drug loading for enhanced cancer therapyEffect of particle size on the cellular uptake and anti-inflammatory activity of oral nanotherapeuticsMethotrexate-based amphiphilic prodrug nanoaggregates for co-administration of multiple therapeutics and synergistic cancer therapyAn NIR-light-responsive surface molecularly imprinted polymer for photoregulated drug release in aqueous solution through porcine tissueSilk fibroin-based nanotherapeutics: application in the treatment of colonic diseasesMulti-bioresponsive silk fibroin-based nanoparticles with on-demand cytoplasmic drug release capacity for CD44-targeted alleviation of ulcerative colitisTopical application of silk fibroin-based hydrogel in preventing hypertrophic scarsModulation of drug release by decoration with Pluronic F127 to improve anti-colon cancer activity of electrospun fibrous meshesLycium barbarum lipid-based edible nanoparticles protect against experimental colitisOral administration of chondroitin sulfate-functionalized nanoparticles for colonic macrophage-targeted drug deliveryFacile Fabrication of Oxidation-Responsive Polymeric Nanoparticles for Effective Anticancer Drug Delivery
P50
Q28394225-5F85607A-5829-4B48-A2DA-047D9C5993E2Q35119565-E1967A16-6DD4-4D3B-9917-FDB43704F356Q36042167-B8FE62AC-DEF2-476A-9894-52420B31FB41Q36201940-E5D68644-9B99-4A76-8111-32AA19389427Q36326103-40B39F05-EFCE-4615-B646-455A3439CBDFQ36646618-6B3A8601-47DF-4F38-89DD-F3EB258D3D81Q37119616-CDCB14D8-3C4C-4774-91DD-74A7CA68E59EQ37146028-E92963BB-2191-446E-8313-C2CF3C9975FEQ37469872-0183CF67-B694-4385-AED4-057EB6943ECDQ37690479-08BED663-1394-4AE7-B6CF-FE0827AEBF3AQ37695146-2314A12E-8138-4BC4-BA93-51345172FD7CQ38049367-30535935-D400-447B-B360-782DD721E9A8Q38834450-254B9E71-43D5-4B5A-A9FD-D2FAC142920FQ38874499-B0970894-5DF9-49BB-8007-7F786AB110AFQ38997094-6D22A674-9671-403B-9C77-4BD1567B381EQ46272530-1E019DDF-9EC5-4461-9E43-F08D9779B513Q47598918-92B83602-F266-4C16-B1F6-3331CAE31C17Q47815925-D5EB23C0-01E2-4783-A032-ADAB5BDA35CBQ47980720-E82431E7-A098-4324-BCA5-A5CB4FCF105FQ48020807-D13675D0-54E1-48DA-BFB3-9C204B98B773Q48039277-7A7E56E3-A783-47F8-9C8F-3F08A70D3535Q57284623-64BEAC5C-9BEF-41DB-8938-5098CE7FB8B9Q88962756-ED71E499-F42C-4824-B06B-2E8834428A21Q89365469-48B33966-D4BF-4026-8D5C-CB43E0E4F2ABQ89881251-2DAF0964-A095-43C6-A357-23EBA3619F94Q90100889-1DAE7BD4-0D2B-47E1-9CBA-0CC9B3092B90Q91382901-3610970A-35B5-4803-9F6F-98D705FCFD22Q91761536-6DA752DA-B680-40F0-8201-9686B4CEE0FEQ92137621-01776EFA-BF45-4F83-8481-0928D8CC192FQ92177211-49A04D9A-3D32-4D2D-B247-8BD1E0B00B28Q92482308-A62B9475-D74A-44F9-8A7F-29759E684520Q92561254-147FB81A-5C4C-44A9-86B6-2CBA2029F8FEQ92706109-3D7FB2F8-25EC-408F-A6B9-472DEC5BB60FQ93366947-2E2DCC13-82B2-406E-922F-45E53E0B05BF
P50
description
researcher (ORCID 0000-0002-2992-6435)
@en
name
Bo Xiao
@en
type
label
Bo Xiao
@en
prefLabel
Bo Xiao
@en
P31
P496
0000-0002-2992-6435